Revelation Biosciences reports Q1 EPS ($2.11), consensus ($6.88)

As of March 31, 2025, Revelation had $3.7M in cash and cash equivalents, compared to $6.5M as of December 31, 2024. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through June 2025. “While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe burns,” said James Rolke, Chief Executive Officer of Revelation. “We are also looking forward to the Phase 1b PRIME clinical study topline data this summer.”